Competitive Inhibitor
Competitive Inhibitor - Related Videos
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
0 Views •
Cited by 4 •
2015
We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
07:42
Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition
0 Views •
Cited by 19 •
2016
The deferred growth inhibition assay can be used to assess the competition effect by one bacterial isolate on another. Inhibition is quantified by measuring the zone of clearing around the inhibitor-producing isolate, or qualitatively assessed by determining the visible extent of inhibition.
09:16
Oligopeptide Competition Assay for Phosphorylation Site Determination
0 Views •
Cited by 3 •
2017
Peptide competition assays are widely used in a variety of molecular and immunological experiments. This paper describes a detailed method for an in vitro oligopeptide-competing kinase assay and the associated validation procedures, which may be useful to find specific phosphorylation sites.
14:22
ELISA Assays: Indirect, Sandwich, and Competitive
0 Views •
2023
Source: Whitney Swanson1,2, Frances V. Sjaastad2,3, and Thomas S. Griffith1,2,3,4 1 Department of Urology, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Enzyme-linked immunosorbent assay (ELISA) is frequently used to measure the presence...
FAQs
The inhibitor and substrate compete for a limited number of active-site opportunities. When substrate concentration rises, substrate molecules are more likely to occupy the site before the inhibitor does. This shifts binding toward substrate use and can lessen inhibition, while the enzyme can still reach the same maximum catalytic capacity under suitable conditions.
Reversible binding allows the inhibitor to associate with and leave the enzyme’s active site rather than permanently disabling the enzyme. Because substrate and inhibitor access the same location, their relative concentrations influence which molecule occupies it at a given time. This reversibility explains why changing cellular conditions can alter the observed level of inhibition.
Structural resemblance helps the inhibitor fit the enzyme’s active site, the region normally contacted by the substrate. Once bound there, it prevents substrate access without requiring permanent enzyme damage. This molecular mimicry gives competitive inhibition its selectivity and explains how a compound can interfere with one enzyme’s activity through competition at a particular binding location.
Competitive inhibition reduces access to the active site at a given substrate concentration, but it does not necessarily alter the enzyme’s maximum catalytic capacity. With enough substrate, substrate molecules can outcompete the inhibitor and allow the enzyme to operate at that capacity. This distinction helps separate reduced access from a change in catalytic potential.
Cells can use competition at enzyme active sites to adjust pathway activity as molecular conditions change. The balance between available substrate and inhibitor influences how much enzyme participates in catalysis. Because increasing substrate can lessen the inhibition, this mechanism links enzyme output to changing concentrations and provides a way to interpret metabolic regulation.
Drug designers can develop compounds that occupy the active sites of selected enzymes and reduce their activity through competition with the normal substrate. The approach is relevant when blocking a particular enzyme could affect infection, signaling, or disease. Selectivity is important because the intended outcome depends on targeting the enzyme involved in the biological process of interest.